A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia

To evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica versus febuxostat and placebo on reduction in serum uric acid levels in subjects with hyperuricemia. A total of 110 eligible subjects with hyperuricemia were enrolled and randomi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology: advances and applications 2016-01, Vol.8 (Issue 1), p.51-59
Main Authors: Usharani, Pingali, Nutalapati, Chandrasekhar, Pokuri, Venkata Kishan, Kumar, Chiranjeevi Uday, Taduri, Gangadhar
Format: Article
Language:English
Subjects:
Antioxidants
Arthritis
Chromatography
Double-blind studies
Enzymes
Febuxostat
Food
Free radicals
Herbal medicine
Hyperuricemia
Kidney diseases
Metabolism
Original Research
Rheumatism
Terminalia bellerica
Terminalia chebula
Uric acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica versus febuxostat and placebo on reduction in serum uric acid levels in subjects with hyperuricemia. A total of 110 eligible subjects with hyperuricemia were enrolled and randomized to either of the five treatment groups - T. chebula 500 mg twice a day (BID), T. bellerica 250 mg BID, T. bellerica 500 mg BID, placebo BID, and febuxostat 40 mg once daily plus an identical placebo - for a duration of 24 weeks. Serum uric acid levels were measured at baseline and at the end of 4, 8, 12, 16, 20, and 24 weeks. Statistical analysis was done using GraphPad Prism Software 4. All active treatment groups showed a reduction in serum uric acid levels compared to baseline and placebo. Significant reduction in mean serum uric acid levels started as early as 4 weeks following treatment, compared to baseline, with T. bellerica (500 and 250 mg), febuxostat (P
ISSN:1179-1438
1179-1438
DOI:10.2147/CPAA.S100521